http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 03 Jun 2026 06:05:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ALTERITY+THERAPEUTICS+++++For%3A+Jun+30/26594902.html si-local-file:///var/storage/secattach/20260603/26594902.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ALTERITY+THERAPEUTICS+++++For%3A+Jun+30/26594902.html Wed, 03 Jun 2026 06:05:00 -0400 ATHE O.00730626 PBN http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ALTERITY+THERAPEUTICS+++++For%3A+Jun+30/26594902.html si-local-file:///var/storage/secattach/20260603/26594902.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ALTERITY+THERAPEUTICS+++++For%3A+Jun+30/26594902.html Wed, 03 Jun 2026 06:05:00 -0400 ATHE O.00730626 PBN http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ALTERITY+THERAPEUTICS+++++For%3A+Jun+30/26594902.html si-local-file:///var/storage/secattach/20260603/26594902.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ALTERITY+THERAPEUTICS+++++For%3A+Jun+30/26594902.html Wed, 03 Jun 2026 06:05:00 -0400 ATHE O.00730626 PBN http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ALTERITY+THERAPEUTICS+++++For%3A+May+31/26570414.html si-local-file:///var/storage/secattach/20260529/26570414.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ALTERITY+THERAPEUTICS+++++For%3A+May+31/26570414.html Fri, 29 May 2026 06:07:00 -0400 ATHE O.00730626 PBN http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ALTERITY+THERAPEUTICS+++++For%3A+May+31/26570414.html si-local-file:///var/storage/secattach/20260529/26570414.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ALTERITY+THERAPEUTICS+++++For%3A+May+31/26570414.html Fri, 29 May 2026 06:07:00 -0400 ATHE O.00730626 PBN http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ALTERITY+THERAPEUTICS+++++For%3A+May+31/26570414.html si-local-file:///var/storage/secattach/20260529/26570414.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ALTERITY+THERAPEUTICS+++++For%3A+May+31/26570414.html Fri, 29 May 2026 06:07:00 -0400 ATHE O.00730626 PBN http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html <p>Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) presented data from three medical conferences supporting the advancement of its drug candidate ATH434 into Phase 3 clinical development for Multiple System Atrophy, according to a company statement.</p> <p>The presentations included research from Vanderbilt University Medical Center showing that quantitative susceptibility mapping can detect progressive iron accumulation in early MSA stages. The MRI imaging approach demonstrated the ability to detect iron dysregulation before clinical diagnosis and track progression over 12 months.</p> <p>Results from the company's Phase 2 trial showed ATH434 slowed functional decline in MSA patients. The 50 mg twice-daily dose produced a statistically significant effect http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html Tue, 19 May 2026 07:25:17 -0400 A.06822034 A.19718279 A.31293549 A.50216778 A.60012004 ATH ATH.AX ATHE O.00573636 O.00730626 O.01304637 O.01951358 O.20026344 O.21962133 http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html <p>Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) presented data from three medical conferences supporting the advancement of its drug candidate ATH434 into Phase 3 clinical development for Multiple System Atrophy, according to a company statement.</p> <p>The presentations included research from Vanderbilt University Medical Center showing that quantitative susceptibility mapping can detect progressive iron accumulation in early MSA stages. The MRI imaging approach demonstrated the ability to detect iron dysregulation before clinical diagnosis and track progression over 12 months.</p> <p>Results from the company's Phase 2 trial showed ATH434 slowed functional decline in MSA patients. The 50 mg twice-daily dose produced a statistically significant effect http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html Tue, 19 May 2026 07:25:17 -0400 A.06822034 A.19718279 A.31293549 A.50216778 A.60012004 ATH ATH.AX ATHE O.00573636 O.00730626 O.01304637 O.01951358 O.20026344 O.21962133 http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html <p>Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) presented data from three medical conferences supporting the advancement of its drug candidate ATH434 into Phase 3 clinical development for Multiple System Atrophy, according to a company statement.</p> <p>The presentations included research from Vanderbilt University Medical Center showing that quantitative susceptibility mapping can detect progressive iron accumulation in early MSA stages. The MRI imaging approach demonstrated the ability to detect iron dysregulation before clinical diagnosis and track progression over 12 months.</p> <p>Results from the company's Phase 2 trial showed ATH434 slowed functional decline in MSA patients. The 50 mg twice-daily dose produced a statistically significant effect http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html Tue, 19 May 2026 07:25:17 -0400 A.06822034 A.19718279 A.31293549 A.50216778 A.60012004 ATH ATH.AX ATHE O.00573636 O.00730626 O.01304637 O.01951358 O.20026344 O.21962133 http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html <p>Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) presented data from three medical conferences supporting the advancement of its drug candidate ATH434 into Phase 3 clinical development for Multiple System Atrophy, according to a company statement.</p> <p>The presentations included research from Vanderbilt University Medical Center showing that quantitative susceptibility mapping can detect progressive iron accumulation in early MSA stages. The MRI imaging approach demonstrated the ability to detect iron dysregulation before clinical diagnosis and track progression over 12 months.</p> <p>Results from the company's Phase 2 trial showed ATH434 slowed functional decline in MSA patients. The 50 mg twice-daily dose produced a statistically significant effect http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html Tue, 19 May 2026 07:25:17 -0400 A.06822034 A.19718279 A.31293549 A.50216778 A.60012004 ATH ATH.AX ATHE O.00573636 O.00730626 O.01304637 O.01951358 O.20026344 O.21962133 http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html <p>Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) presented data from three medical conferences supporting the advancement of its drug candidate ATH434 into Phase 3 clinical development for Multiple System Atrophy, according to a company statement.</p> <p>The presentations included research from Vanderbilt University Medical Center showing that quantitative susceptibility mapping can detect progressive iron accumulation in early MSA stages. The MRI imaging approach demonstrated the ability to detect iron dysregulation before clinical diagnosis and track progression over 12 months.</p> <p>Results from the company's Phase 2 trial showed ATH434 slowed functional decline in MSA patients. The 50 mg twice-daily dose produced a statistically significant effect http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html Tue, 19 May 2026 07:25:17 -0400 A.06822034 A.19718279 A.31293549 A.50216778 A.60012004 ATH ATH.AX ATHE O.00573636 O.00730626 O.01304637 O.01951358 O.20026344 O.21962133 http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html <p>Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) presented data from three medical conferences supporting the advancement of its drug candidate ATH434 into Phase 3 clinical development for Multiple System Atrophy, according to a company statement.</p> <p>The presentations included research from Vanderbilt University Medical Center showing that quantitative susceptibility mapping can detect progressive iron accumulation in early MSA stages. The MRI imaging approach demonstrated the ability to detect iron dysregulation before clinical diagnosis and track progression over 12 months.</p> <p>Results from the company's Phase 2 trial showed ATH434 slowed functional decline in MSA patients. The 50 mg twice-daily dose produced a statistically significant effect http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html Tue, 19 May 2026 07:25:17 -0400 A.06822034 A.19718279 A.31293549 A.50216778 A.60012004 ATH ATH.AX ATHE O.00573636 O.00730626 O.01304637 O.01951358 O.20026344 O.21962133 http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html <p>Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) presented data from three medical conferences supporting the advancement of its drug candidate ATH434 into Phase 3 clinical development for Multiple System Atrophy, according to a company statement.</p> <p>The presentations included research from Vanderbilt University Medical Center showing that quantitative susceptibility mapping can detect progressive iron accumulation in early MSA stages. The MRI imaging approach demonstrated the ability to detect iron dysregulation before clinical diagnosis and track progression over 12 months.</p> <p>Results from the company's Phase 2 trial showed ATH434 slowed functional decline in MSA patients. The 50 mg twice-daily dose produced a statistically significant effect http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html Tue, 19 May 2026 07:25:17 -0400 A.06822034 A.19718279 A.31293549 A.50216778 A.60012004 ATH ATH.AX ATHE O.00573636 O.00730626 O.01304637 O.01951358 O.20026344 O.21962133 http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html <p>Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) presented data from three medical conferences supporting the advancement of its drug candidate ATH434 into Phase 3 clinical development for Multiple System Atrophy, according to a company statement.</p> <p>The presentations included research from Vanderbilt University Medical Center showing that quantitative susceptibility mapping can detect progressive iron accumulation in early MSA stages. The MRI imaging approach demonstrated the ability to detect iron dysregulation before clinical diagnosis and track progression over 12 months.</p> <p>Results from the company's Phase 2 trial showed ATH434 slowed functional decline in MSA patients. The 50 mg twice-daily dose produced a statistically significant effect http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html Tue, 19 May 2026 07:25:17 -0400 A.06822034 A.19718279 A.31293549 A.50216778 A.60012004 ATH ATH.AX ATHE O.00573636 O.00730626 O.01304637 O.01951358 O.20026344 O.21962133 http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html <p>Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) presented data from three medical conferences supporting the advancement of its drug candidate ATH434 into Phase 3 clinical development for Multiple System Atrophy, according to a company statement.</p> <p>The presentations included research from Vanderbilt University Medical Center showing that quantitative susceptibility mapping can detect progressive iron accumulation in early MSA stages. The MRI imaging approach demonstrated the ability to detect iron dysregulation before clinical diagnosis and track progression over 12 months.</p> <p>Results from the company's Phase 2 trial showed ATH434 slowed functional decline in MSA patients. The 50 mg twice-daily dose produced a statistically significant effect http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html Tue, 19 May 2026 07:25:17 -0400 A.06822034 A.19718279 A.31293549 A.50216778 A.60012004 ATH ATH.AX ATHE O.00573636 O.00730626 O.01304637 O.01951358 O.20026344 O.21962133 http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html <p>Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) presented data from three medical conferences supporting the advancement of its drug candidate ATH434 into Phase 3 clinical development for Multiple System Atrophy, according to a company statement.</p> <p>The presentations included research from Vanderbilt University Medical Center showing that quantitative susceptibility mapping can detect progressive iron accumulation in early MSA stages. The MRI imaging approach demonstrated the ability to detect iron dysregulation before clinical diagnosis and track progression over 12 months.</p> <p>Results from the company's Phase 2 trial showed ATH434 slowed functional decline in MSA patients. The 50 mg twice-daily dose produced a statistically significant effect http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html Tue, 19 May 2026 07:25:17 -0400 A.06822034 A.19718279 A.31293549 A.50216778 A.60012004 ATH ATH.AX ATHE O.00573636 O.00730626 O.01304637 O.01951358 O.20026344 O.21962133 http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html <p>Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) presented data from three medical conferences supporting the advancement of its drug candidate ATH434 into Phase 3 clinical development for Multiple System Atrophy, according to a company statement.</p> <p>The presentations included research from Vanderbilt University Medical Center showing that quantitative susceptibility mapping can detect progressive iron accumulation in early MSA stages. The MRI imaging approach demonstrated the ability to detect iron dysregulation before clinical diagnosis and track progression over 12 months.</p> <p>Results from the company's Phase 2 trial showed ATH434 slowed functional decline in MSA patients. The 50 mg twice-daily dose produced a statistically significant effect http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html Tue, 19 May 2026 07:25:17 -0400 A.06822034 A.19718279 A.31293549 A.50216778 A.60012004 ATH ATH.AX ATHE O.00573636 O.00730626 O.01304637 O.01951358 O.20026344 O.21962133 http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html <p>Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) presented data from three medical conferences supporting the advancement of its drug candidate ATH434 into Phase 3 clinical development for Multiple System Atrophy, according to a company statement.</p> <p>The presentations included research from Vanderbilt University Medical Center showing that quantitative susceptibility mapping can detect progressive iron accumulation in early MSA stages. The MRI imaging approach demonstrated the ability to detect iron dysregulation before clinical diagnosis and track progression over 12 months.</p> <p>Results from the company's Phase 2 trial showed ATH434 slowed functional decline in MSA patients. The 50 mg twice-daily dose produced a statistically significant effect http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html Tue, 19 May 2026 07:25:17 -0400 A.06822034 A.19718279 A.31293549 A.50216778 A.60012004 ATH ATH.AX ATHE O.00573636 O.00730626 O.01304637 O.01951358 O.20026344 O.21962133 http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html <p>Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) presented data from three medical conferences supporting the advancement of its drug candidate ATH434 into Phase 3 clinical development for Multiple System Atrophy, according to a company statement.</p> <p>The presentations included research from Vanderbilt University Medical Center showing that quantitative susceptibility mapping can detect progressive iron accumulation in early MSA stages. The MRI imaging approach demonstrated the ability to detect iron dysregulation before clinical diagnosis and track progression over 12 months.</p> <p>Results from the company's Phase 2 trial showed ATH434 slowed functional decline in MSA patients. The 50 mg twice-daily dose produced a statistically significant effect http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html Tue, 19 May 2026 07:25:17 -0400 A.06822034 A.19718279 A.31293549 A.50216778 A.60012004 ATH ATH.AX ATHE O.00573636 O.00730626 O.01304637 O.01951358 O.20026344 O.21962133 http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html <p>Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) presented data from three medical conferences supporting the advancement of its drug candidate ATH434 into Phase 3 clinical development for Multiple System Atrophy, according to a company statement.</p> <p>The presentations included research from Vanderbilt University Medical Center showing that quantitative susceptibility mapping can detect progressive iron accumulation in early MSA stages. The MRI imaging approach demonstrated the ability to detect iron dysregulation before clinical diagnosis and track progression over 12 months.</p> <p>Results from the company's Phase 2 trial showed ATH434 slowed functional decline in MSA patients. The 50 mg twice-daily dose produced a statistically significant effect http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html Tue, 19 May 2026 07:25:17 -0400 A.06822034 A.19718279 A.31293549 A.50216778 A.60012004 ATH ATH.AX ATHE O.00573636 O.00730626 O.01304637 O.01951358 O.20026344 O.21962133 http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Data+Presentations+Support+Advancement+of+ATH434+into+Phase+3+in+Multiple+System+Atrophy/26517233.html <p align="center"><em>– Alterity’s novel imaging and biomarker approach positions the Company at the forefront of clinical research in MSA – </em></p> <p align="center"><em>– End-of-Phase 2 FDA Meeting on track for mid-2026 to confirm path forward for Phase 3 – </em></p> <p align="justify">MELBOURNE, Australia AND SAN FRANCISCO, May 19, 2026 (GLOBE NEWSWIRE) --   <a target="_blank" href="https://www.globenewswire.com/Tracker?data=4nCgxhdCsmEcuzLPUZCbuAkJ1vif4elpf2JiKMSqHRrNUxhtndtwGHhNsUZL49gtNgfMKiWetokD6ILB5F2DUV6l7x7Lkdo56LSTKgdDFhI=" rel="nofollow" target="_blank">Alterity Therapeutics</a> (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that presentations related to the Company’s development program in Multiple System Atrophy (MSA) were delivered at three http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Data+Presentations+Support+Advancement+of+ATH434+into+Phase+3+in+Multiple+System+Atrophy/26517233.html Tue, 19 May 2026 07:25:00 -0400 A.06822034 A.19718279 A.31293549 A.50216778 A.60012004 ATH ATH.AX ATHE O.00573636 O.00730626 O.01304637 O.01951358 O.20026344 O.21962133 http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Data+Presentations+Support+Advancement+of+ATH434+into+Phase+3+in+Multiple+System+Atrophy/26517233.html <p align="center"><em>– Alterity’s novel imaging and biomarker approach positions the Company at the forefront of clinical research in MSA – </em></p> <p align="center"><em>– End-of-Phase 2 FDA Meeting on track for mid-2026 to confirm path forward for Phase 3 – </em></p> <p align="justify">MELBOURNE, Australia AND SAN FRANCISCO, May 19, 2026 (GLOBE NEWSWIRE) --   <a target="_blank" href="https://www.globenewswire.com/Tracker?data=4nCgxhdCsmEcuzLPUZCbuAkJ1vif4elpf2JiKMSqHRrNUxhtndtwGHhNsUZL49gtNgfMKiWetokD6ILB5F2DUV6l7x7Lkdo56LSTKgdDFhI=" rel="nofollow" target="_blank">Alterity Therapeutics</a> (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that presentations related to the Company’s development program in Multiple System Atrophy (MSA) were delivered at three http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Data+Presentations+Support+Advancement+of+ATH434+into+Phase+3+in+Multiple+System+Atrophy/26517233.html Tue, 19 May 2026 07:25:00 -0400 A.06822034 A.19718279 A.31293549 A.50216778 A.60012004 ATH ATH.AX ATHE O.00573636 O.00730626 O.01304637 O.01951358 O.20026344 O.21962133 http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Data+Presentations+Support+Advancement+of+ATH434+into+Phase+3+in+Multiple+System+Atrophy/26517233.html <p align="center"><em>– Alterity’s novel imaging and biomarker approach positions the Company at the forefront of clinical research in MSA – </em></p> <p align="center"><em>– End-of-Phase 2 FDA Meeting on track for mid-2026 to confirm path forward for Phase 3 – </em></p> <p align="justify">MELBOURNE, Australia AND SAN FRANCISCO, May 19, 2026 (GLOBE NEWSWIRE) --   <a target="_blank" href="https://www.globenewswire.com/Tracker?data=4nCgxhdCsmEcuzLPUZCbuAkJ1vif4elpf2JiKMSqHRrNUxhtndtwGHhNsUZL49gtNgfMKiWetokD6ILB5F2DUV6l7x7Lkdo56LSTKgdDFhI=" rel="nofollow" target="_blank">Alterity Therapeutics</a> (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that presentations related to the Company’s development program in Multiple System Atrophy (MSA) were delivered at three http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Data+Presentations+Support+Advancement+of+ATH434+into+Phase+3+in+Multiple+System+Atrophy/26517233.html Tue, 19 May 2026 07:25:00 -0400 A.06822034 A.19718279 A.31293549 A.50216778 A.60012004 ATH ATH.AX ATHE O.00573636 O.00730626 O.01304637 O.01951358 O.20026344 O.21962133 http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Data+Presentations+Support+Advancement+of+ATH434+into+Phase+3+in+Multiple+System+Atrophy/26517233.html <p align="center"><em>– Alterity’s novel imaging and biomarker approach positions the Company at the forefront of clinical research in MSA – </em></p> <p align="center"><em>– End-of-Phase 2 FDA Meeting on track for mid-2026 to confirm path forward for Phase 3 – </em></p> <p align="justify">MELBOURNE, Australia AND SAN FRANCISCO, May 19, 2026 (GLOBE NEWSWIRE) --   <a target="_blank" href="https://www.globenewswire.com/Tracker?data=4nCgxhdCsmEcuzLPUZCbuAkJ1vif4elpf2JiKMSqHRrNUxhtndtwGHhNsUZL49gtNgfMKiWetokD6ILB5F2DUV6l7x7Lkdo56LSTKgdDFhI=" rel="nofollow" target="_blank">Alterity Therapeutics</a> (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that presentations related to the Company’s development program in Multiple System Atrophy (MSA) were delivered at three http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Data+Presentations+Support+Advancement+of+ATH434+into+Phase+3+in+Multiple+System+Atrophy/26517233.html Tue, 19 May 2026 07:25:00 -0400 A.06822034 A.19718279 A.31293549 A.50216778 A.60012004 ATH ATH.AX ATHE O.00573636 O.00730626 O.01304637 O.01951358 O.20026344 O.21962133 http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Data+Presentations+Support+Advancement+of+ATH434+into+Phase+3+in+Multiple+System+Atrophy/26517233.html <p align="center"><em>– Alterity’s novel imaging and biomarker approach positions the Company at the forefront of clinical research in MSA – </em></p> <p align="center"><em>– End-of-Phase 2 FDA Meeting on track for mid-2026 to confirm path forward for Phase 3 – </em></p> <p align="justify">MELBOURNE, Australia AND SAN FRANCISCO, May 19, 2026 (GLOBE NEWSWIRE) --   <a target="_blank" href="https://www.globenewswire.com/Tracker?data=4nCgxhdCsmEcuzLPUZCbuAkJ1vif4elpf2JiKMSqHRrNUxhtndtwGHhNsUZL49gtNgfMKiWetokD6ILB5F2DUV6l7x7Lkdo56LSTKgdDFhI=" rel="nofollow" target="_blank">Alterity Therapeutics</a> (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that presentations related to the Company’s development program in Multiple System Atrophy (MSA) were delivered at three http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Data+Presentations+Support+Advancement+of+ATH434+into+Phase+3+in+Multiple+System+Atrophy/26517233.html Tue, 19 May 2026 07:25:00 -0400 A.06822034 A.19718279 A.31293549 A.50216778 A.60012004 ATH ATH.AX ATHE O.00573636 O.00730626 O.01304637 O.01951358 O.20026344 O.21962133